Gilead Sciences
GILD
$129.67
+0.07%
Gilead Sciences is a global biopharmaceutical company that develops and commercializes therapies for life-threatening infectious diseases, with a core portfolio in HIV and viral hepatitis, and a growing presence in oncology. The company is a market leader in antiviral therapies and has established itself as a significant player in cell therapy through strategic acquisitions. The current investor narrative is dominated by the company's aggressive acquisition strategy to bolster its long-term oncology and immunology pipelines, as evidenced by recent multi-billion dollar deals for Tubulis and Arcellx, which are seen as bets on future growth but also raise questions about near-term capital allocation and integration execution.…
GILD
Gilead Sciences
$129.67
Related headlines
GILD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $168.57 and implied upside of +30.0% versus the current price.
Average Target
$168.57
16 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$104 - $169
Analyst target range
Analyst coverage is robust with 16 analysts providing estimates, indicating strong institutional interest. The consensus sentiment leans bullish, as evidenced by the recent institutional ratings which include multiple 'Buy' and 'Overweight' actions from firms like Needham, Truist, UBS, and Wells Fargo in early 2026, with no downgrades noted. The average target price implied by the estimated EPS of $12.89 and the forward PE of 13.48x is approximately $173.80, which represents a potential upside of about 34% from the current price of $129.58. The target range for estimated EPS is wide, from a low of $12.43 to a high of $13.50, reflecting differing assumptions about the success of the oncology pipeline, integration of acquisitions, and the sustainability of HIV franchise earnings. The high-end targets likely assume successful commercialization of newly acquired assets like Arcellx's myeloma therapy and margin expansion, while the low-end may factor in competitive pressures, pipeline delays, or acquisition-related dilution. The recent pattern of reiterated bullish ratings amidst the stock's price decline suggests analysts view the pullback as a buying opportunity, maintaining conviction in the long-term strategy.
Bulls vs Bears: GILD Investment Factors
The investment debate for Gilead Sciences centers on a clash between its strong fundamental foundation and its challenged near-term price action. The bull case is supported by robust cash generation, analyst conviction, an attractive forward valuation, and a strategic pivot to oncology growth. The bear case highlights severe technical deterioration, a valuation that prices in much success, and significant execution risk from an aggressive acquisition strategy. Currently, the bearish evidence from momentum and valuation appears more pressing in the short term, though the fundamental bullish pillars provide a solid floor. The single most important tension is the market's patience: will Gilead's multi-billion dollar oncology bets pay off before investor sentiment, eroded by the recent sharp decline, forces a further valuation derating?
Bullish
- Strong Free Cash Flow Generation: The company generated $9.46 billion in trailing twelve-month free cash flow, providing ample internal capital to fund its aggressive acquisition strategy and dividend payments without straining its balance sheet. This robust cash generation underpins the company's strategic flexibility and financial health.
- Analyst Conviction Amid Pullback: Analyst consensus remains bullish with an average target price of ~$173.80, implying a 34% upside from the current price of $129.58. Recent institutional actions from firms like Needham and UBS in early 2026 have been 'Buy' or 'Overweight' ratings, suggesting the recent price decline is viewed as a buying opportunity.
- Attractive Forward Valuation: The forward P/E of 13.48x is significantly lower than the trailing P/E of 17.94x, indicating the market expects meaningful earnings growth. This forward multiple appears reasonable for a large-cap pharma with a stable core business and growth initiatives, offering a potential valuation re-rating if growth materializes.
- Solid Core Profitability: The company maintains strong operational efficiency with a Q4 2025 gross margin of 86.84% and an operating margin of 39.7%. A full-year net margin of 28.9% and an ROE of 37.6% demonstrate the underlying profitability and efficient use of equity from its dominant HIV franchise.
Bearish
- Severe Recent Momentum Breakdown: The stock has underperformed significantly, down 7.29% over the past month and 16.39% over three months, with relative strength figures of -12.89 and -24.81 against the market. This sharp reversal from a 29% yearly gain signals a significant loss of momentum and potential trend change, with the price now at 82% of its 52-week range.
- Valuation at High End of Historical Range: The trailing P/E of 17.94x is towards the higher end of its recent historical range (approximately 11x to 26x over two years). Trading near this upper band suggests much of the optimism around its growth strategy is already priced in, leaving limited room for multiple expansion and increasing sensitivity to execution risks.
- Acquisition Execution & Integration Risk: The aggressive acquisition spree (e.g., $7.8B for Arcellx, $3.15B for Tubulis) raises near-term capital allocation and integration execution questions. These deals are bets on future growth (e.g., Arcellx's myeloma therapy expected to boost earnings from 2028), creating a multi-year period of uncertainty and potential dilution before benefits are realized.
- Modest Core Revenue Growth: Q4 2025 revenue grew only 4.7% year-over-year to $7.93 billion. While sequential growth from $6.67B in Q1 is positive, the overall growth rate is modest and heavily reliant on the mature HIV franchise ($5.8B in 'Other HIV' sales), highlighting the need for successful pipeline commercialization to accelerate top-line expansion.
GILD Technical Analysis
The stock is in a sustained uptrend over the past year, with a 1-year price change of +29.14%, significantly outperforming the SPY's +25.19% gain. However, the current price of $129.58 sits at approximately 82% of its 52-week range ($100.23 to $157.29), indicating it has retreated meaningfully from its highs and is now in a consolidation phase. This positioning suggests the strong momentum has cooled, and the stock is testing support levels after a significant run-up. Recent momentum has turned sharply negative, with the stock down -7.29% over the past month and -16.39% over the past three months, a stark divergence from the positive yearly trend. This underperformance is pronounced relative to the market, as shown by the -12.89 and -24.81 relative strength figures for the 1-month and 3-month periods, respectively, signaling a significant loss of momentum and potential trend reversal or deep correction. Key technical support is at the 52-week low of $100.23, while immediate resistance is at the recent high near $157.29. A breakdown below the recent April low of $127.75 could signal a deeper correction toward the $118-$120 zone, while a recovery above $150 is needed to re-establish the bullish trend. The stock's low beta of 0.33 indicates it is historically about 67% less volatile than the broader market, which suggests the recent sharp declines are unusual and may reflect company-specific news or sector rotation rather than broad market moves.
Beta
0.33
0.33x market volatility
Max Drawdown
-18.0%
Largest decline past year
52-Week Range
$103-$157
Price range past year
Annual Return
+26.5%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | -5.8% | +4.0% |
| 3m | -16.5% | +8.2% |
| 6m | +1.2% | +11.5% |
| 1y | +26.5% | +24.3% |
| ytd | +6.6% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $7.93 billion representing a 4.7% year-over-year increase. The multi-quarter trend shows revenue has grown sequentially from $6.67B in Q1 to $7.93B in Q4, indicating steady, albeit not explosive, growth. Segment data reveals the core HIV franchise, with $5.8 billion in 'Other HIV' sales, remains the dominant driver, while newer oncology assets like Cell Therapy ($627M) and Trodelvy ($383M) are contributing meaningfully, though Veklury (remdesivir) sales have dwindled to $211 million. The company is solidly profitable, with Q4 2025 net income of $2.18 billion and a robust gross margin of 86.84%. Profitability has been volatile quarter-to-quarter, as seen in the jump from Q3 net income of $3.05 billion to Q4's $2.18 billion, but the full-year trend remains positive with a net margin of 28.9%. The operating margin of 39.7% is healthy and indicative of strong operational efficiency in its core business. The balance sheet is leveraged but manageable, with a debt-to-equity ratio of 1.09. Financial health is supported by substantial cash generation, with trailing twelve-month free cash flow of $9.46 billion, yielding a strong FCF yield relative to its market cap. The current ratio of 1.68 and an ROE of 37.6% demonstrate solid liquidity and efficient use of shareholder equity, providing ample internal funding for its acquisition-led growth strategy and dividend payments.
Quarterly Revenue
$7.9B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Given the consistently positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 17.94x, while the forward PE is notably lower at 13.48x. This significant gap implies the market expects meaningful earnings growth in the coming year, likely factoring in contributions from recent acquisitions and pipeline advancements. Compared to industry averages, Gilead's trailing PE of 17.94x is difficult to contextualize precisely without a provided sector average, but its forward multiple of 13.48x appears reasonable for a large-cap pharmaceutical company with stable cash flows and growth initiatives. The premium or discount justification hinges on its industry-leading HIV franchise and the growth optionality from its expanding oncology portfolio. Historically, the stock's current trailing PE of 17.94x is towards the higher end of its recent range, as seen in quarterly historical data where it fluctuated between approximately 11x and 26x over the past two years. Trading near the upper end of this band suggests the market has already priced in a fair amount of optimism regarding its growth strategy, leaving less room for multiple expansion and increasing sensitivity to execution risks or pipeline setbacks.
PE
17.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5x~982x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Gilead's primary financial risk stems from its elevated debt-to-equity ratio of 1.09, which, while supported by $9.46B in TTM free cash flow, could constrain flexibility if acquisition integration falters or interest rates rise. Operationally, revenue growth is modest at 4.7% YoY, and profitability is volatile, as seen in the sequential drop from Q3 net income of $3.05B to Q4's $2.18B. The company also faces product concentration risk, with its 'Other HIV' franchise generating $5.8B, underscoring a dependence on this mature segment while newer oncology assets are scaled.
Market & Competitive Risks: The stock trades at a trailing P/E of 17.94x, near the high end of its two-year historical range (approx. 11x-26x), creating valuation compression risk if growth expectations are not met. Its low beta of 0.33 suggests the recent -16.39% 3-month decline is company-specific, likely reflecting investor skepticism about the acquisition spree's near-term payoff. Competitive and regulatory threats persist, including potential pipeline setbacks for acquired assets like Arcellx's myeloma therapy and the evolving pharmaceutical tariff landscape, which could impact industry dynamics.
Worst-Case Scenario: The worst-case scenario involves a failure of key pipeline assets from recent acquisitions, leading to significant write-downs, coupled with sustained margin pressure and a slowdown in the core HIV business. This could trigger multiple compression towards the lower end of its historical P/E range and a loss of investor confidence, driving the stock toward its 52-week low of $100.23. From the current price of $129.58, this represents a realistic downside of approximately -23%. A break below the recent April low of $127.75 could accelerate such a decline.
